Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

China Health Resource (CHRI) Reports Record Second Quarter Results

|Includes: China Health Resource, Inc. (CHRI)

China Health Resource Inc. is a producer and supplier of traditional Chinese medicines. The company’s current line of products are based on Dahurian Angelica Root and are used for the treatment of pain and swelling. It is the only such provider with a nationally certified standard (GAP) in China.

The company today announced robust second quarter earnings for the period ended June 30, 2011. China Health Resource reported over $8 million in revenues and $1.7 million in net income, a 443% increase from the second quarter of 2010. Its net profit margin of 21% was also a large increase from the 10% level of a year ago.

The increases for the first half of 2011 are truly significant for China Health. For instance, the net earnings number for the first six months of this year has already nearly matched the net profit for all of last year.

The company attributes its strong performance to increased sales of raw Dahurian Angelica Root, also known as “Bai Zhi”. In addition, China Health Resource has several other new products making strong headway. These products include Rhizoma Gastrodiae or “TianMa.”

Company Chairman and CEO, Jiayin Wang, said, “We look forward to expansion through both continued sales of our existing lines and introduction of new products consistent with our recognized quality standards.”

For further information on China Health Resource, please visit the company’s website at

Please see disclaimer on the QualityStocks website: